OgCelix provides organoid models derived from human stem cells (iPSC/hSC), patient samples (e.g., tumors and biopsies), and animal tissues. Organoids can be established from multiple organs, including intestine, liver, lung, kidney, and brain—delivering physiologically relevant 3D systems that reproduce essential features of in vivo microenvironment. Each model undergoes comprehensive characterization to ensure long-term stability, batch-to-batch reproducibility, and high biological relevance.
Organoid Establishment service specializes in generating organoid cultures derived from primary tissues (including tumor samples), or induced pluripotent stem cells (iPSCs). Using optimized protocols and culture conditions, we ensure the development of robust, physiologically relevant organoid models that closely mimic native human tissue architecture and signaling environments. These organoids are valuable for a wide range of applications, including drug screening, cancer research, and personalized medicine. Our service supports both short-term and long-term research needs, offering scalable options for high-throughput studies and maintaining the potential for cryopreservation, long-term expansion, and multi-passage stability. By combining the precision of iPSC-based models with the authenticity of patient-derived and primary-tissue–derived organoids, we provide versatile and reliable platforms for advancing translational research and therapeutic development.
Organoid Morphological and Phenotypic AnalysisThe resulting organoid models are characterized using a variety of techniques, including microscopy, immunohistochemistry, gene expression analysis, and functional assays, to assess their structural integrity, cellular composition, and physiological relevance.
Standardized quality control ensures organoid source, functionality, and reproducibility. Morphological analysis includes imaging, IHC, IF staining, and H&E sectioning. Molecular profiling uses RT-qPCR, RNA sequencing, and single-cell transcriptomic analysis. Functional assessments (optional) include electrophysiology, bilirubin metabolism, drug testing, and ion transport, ensuring biological validity for drug discovery and mechanism-of-action studies.
Organoid Model Construction Services content includes but is not limited to：
| Organoid Model Construction Services | ||
|---|---|---|
| Organoid Establishment | Organoid Model Construction, Expansion, and Cryopreservation | |
| Organoid Morphological and Phenotypic Analysis | Organoid Morphological Evaluation | |
| Organoid Morphological Evaluation | ||
| Organoid Total Protein Expression Related Test Evaluation | ||
| Organoid Gene Expression Related Test Evaluation | ||
| Organoid Single Gene Detection (ARMS-PCR) | ||
| Organoid NGS Second-Generation Sequencing Tumor Large Panel Gene Detection (673 Genes) | ||
| Organoid NGS Second-Generation Sequencing Whole Exome Sequencing (WES) | ||
| Organoid NGS Second-Generation Sequencing Whole Genome Sequencing (WGS) | ||
| Organoid Transcriptome Sequencing (RNA-seq) | ||
Delivery content
| Delivery form | Delivery contents |
|---|---|
| Delivery contents | P2/3 generation, 3 vials, ≥2000 organoids per vial |
| Training & QC Report | Bright-field imaging (each generation) |
| Microbial testing (bacteria, fungi, mycoplasma) | |
| H&E staining and surface marker validation | |
| STR authentication | |
| Resuscitation verification |
Key Advantages:
Broad Modeling Capability: Supports multiple tissue types and disease models.
High Biological relevance: Preserves spatial structure and physiological functions of source tissues.
Stringent Quality Control: Available as cryopreserved organoids, sequencing data, or detailed analysis reports.